# Targeted ferroptosis of myofibroblasts by tubeimoside I attenuates hypertrophic scar formation

**Authors:** Jianzhang Wang, Chen Wang, Yulei Jia, Fengchao Chen, Youbin Wang, Juan Du

PMC · DOI: 10.3389/fphar.2025.1654108 · Frontiers in Pharmacology · 2025-09-29

## TL;DR

This study shows that TBMS1 can reduce scar formation by causing cell death in scar-forming cells through a process called ferroptosis.

## Contribution

TBMS1 induces ferroptosis in myofibroblasts, offering a novel therapeutic strategy for hypertrophic scars.

## Key findings

- TBMS1 inhibits myofibroblast proliferation, migration, and activation in vitro.
- TBMS1 triggers ferroptosis via the PI3K/AKT pathway and alters NRF2, SLC40A1, and GPX4 expression.
- In vivo experiments show TBMS1 has antifibrotic effects, reducing scar formation.

## Abstract

Hypertrophic scar (HS), the skin fibroproliferative disease, occurs after burn injury, traumatic injury, and surgery, resulting in high medical and economic burdens. Tubeimoside-I (TBMS1), a triterpenoid saponin monomer obtained from the Chinese medicinal herb Tubeimu, has demonstrated therapeutic potential in various diseases. In the present study, we explored the therapeutic effect of TBMS1 in the progression of HS.

In vitro studies tested the effects of TBMS1 on the biological behaviors of hypertrophic scar fibroblasts (HSFs) were investigated by cell counting kit-8, flow cytometry, wound healing, transwell, and collagen gel contraction assays. Further, the regulatory mechanism of TBMS1 in alleviating HS was elucidated. In vivo experiments were utilized to reveal the influences of TBMS1 on HS formation.

In vitro studies indicated that TBMS1 hindered HSFs proliferation, migration, and myofibroblast activation. The PI3K/AKT signaling pathway mediates TBMS1-induced ferroptosis, which was accompanied by altered expression of NRF2, SLC40A1, and GPX4, ultimately suppressing cell proliferation and collagen synthesis. In vivo experiments confirmed that local TBMS1 injection exerted potent antifibrotic effects.

This study revealed the effect of TBMS1 in activating ferroptosis, suggesting that inducing ferroptosis is probably a novel therapeutic strategy for hypertrophic scar.

## Linked entities

- **Genes:** GABPA (GA binding protein transcription factor subunit alpha) [NCBI Gene 2551], SLC40A1 (solute carrier family 40 member 1) [NCBI Gene 30061], GPX4 (glutathione peroxidase 4) [NCBI Gene 2879], PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207]
- **Chemicals:** Tubeimoside-I (PubChem CID 51346132)
- **Diseases:** HS (MONDO:0019395)

## Full-text entities

- **Genes:** PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, GPX4 (glutathione peroxidase 4) [NCBI Gene 2879] {aka GPx-4, GSHPx-4, MCSP, PHGPx, SMDS, snGPx}, SLC40A1 (solute carrier family 40 member 1) [NCBI Gene 30061] {aka FPN, FPN1, HFE4, IREG1, MST079, MSTP079}
- **Diseases:** HS (MESH:D017439), traumatic injury (MESH:D014947), burn injury (MESH:D002056)
- **Chemicals:** Tubeimoside-I (MESH:C051084), TBMS1 (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12515868/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12515868/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12515868/full.md

---
Source: https://tomesphere.com/paper/PMC12515868